Halozyme Therapeutics (HALO) PT Raised to $79 at TD Cowen

TD Cowen analyst Brendan Smith raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $79.00 (from $77.00) while maintaining a Buy rating.

The analyst comments: "Top/bottom line beat/raise in Q1 is near best-case scenario for HALO made even more impressive given broader biopharma headwinds. Strong royalties from Darzalex/Phesgo strength & Vyvgart Hytrulo's outperformance + raised FY25 guidance support new PT of $79 (+$2). We still see additional upside potential from ongoing launches, buybacks + MRK litigation, all of which reaffirm HALO as a top pick."

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Natera (NTRA) PT Raised to $460 at RBC Capital on 'Strong Setup'
• Camden Property Trust (CPT) PT Lowered to $108 at Truist Securities